Jump to main content
Jump to site search

All chapters
Previous chapter Next chapter

Chapter 7

Anticancer Agent-Incorporating Polymeric Micelles: from Bench to Bedside

There are two main concepts in drug delivery systems (DDS): passive targeting and active targeting. The passive targeting system is achieved by the enhanced permeability and retention effect. Several DDS formulations have been approved worldwide. Regarding a pipeline of clinical development of anticancer agents incorporating a micelle carrier system, several clinical trials are now underway, not only in Japan but also in other countries. A phase 3 trial of NK105, a paclitaxel-incorporating micelle is now underway. In this chapter, preclinical and clinical studies of NK105; NC-6004 a cisplatin-incorporating micelle; and NC-6300, an epirubicin-incorporating micelle are reviewed.

Publication details


Print publication date
28 Apr 2016
Copyright year
2016
Print ISBN
978-1-84973-947-4
PDF eISBN
978-1-78262-253-6
ePub eISBN
978-1-78262-751-7
From the book series:
Drug Discovery